Brief report
and to provide a comprehensive summary of copy-number variants (CNVs) related to prenatal oral cleft cases. Such information will be useful for more informative genetic counseling and decision making regarding invasive prenatal diagnostic testing of fetuses presenting with oral clefts.
MAteRiALs And MetHOds
This is a retrospective analysis of 270 prenatal oral cleft cases referred for CMA by four centers in Hong Kong SAR, mainland of China, and the United States between 2009 and 2012. Initially, a total of 292 prenatal oral cleft cases were referred for CMA. Twenty-one cases were excluded because either the specific type of oral cleft was not documented or the type of clefting reported (such as median cleft, atypical facial cleft, or Pierre Robin) results from a different pathogenesis. 7 One additional case was excluded because the abnormal CMA result was suspected of being a cultural artifact due to extended cell culture time and was not confirmed by subsequent postnatal CMA. CMA was performed utilizing multiple platforms, [9] [10] [11] [12] including both oligonucleotide and bacterial artificial chromosome-based arrays (see details in the Supplementary Materials and Methods online). Quantitative polymerase chain reaction or fluorescence in situ hybridization was used to confirm the imbalances detected by CMA. Parental blood samples were collected when possible to assist with CNV interpretation and to exclude maternal cell contamination. CNVs were categorized as likely benign, pathogenic, or variant of unknown significance. Interpretation of CNV findings was performed in accordance with public and in-house databases, published cases, and clinical assessment by each center. G-banded chromosome analysis following standard protocols was performed or reported for 190 cases. Chromosome analysis was cancelled, not ordered, or results were not provided for the remainder of the cases. All the patients gave consent for analysis with local institutional ethic approval.
ResULts
The cohort of 270 prenatal oral cleft cases was categorized into nonsyndromic and syndromic oral clefts and further subdivided into cleft lip only (CL) or cleft lip with palate (CLP), which also included cleft palate only, resulting in a total of four subgroups ( 10.2-20.4%) was higher (P = 0.2205) than that of traditional chromosome analysis (20/190, 10.5%, 95% CI: 6.1-14.9%). Although the detection rates for the syndromic and nonsyndromic groups were both improved by CMA, the syndromic group had a greater increase of 7.2% compared to the nonsyndromic group with an increase of 1.3%. For both groups, CMA yielded a greater increase in detection of the CL cases as compared with the CLP cases. Of the remaining 80 cases without chromosome analysis results, 11 (13.8%) had pathogenic CNVs, including 6 cases with CNVs <10 Mb that are not likely to be detectable microscopically.
To determine if specific concurrent ultrasound abnormalities were more likely to be associated with pathogenic CNVs, detection rates of pathogenic CNVs were calculated according to specific ultrasound findings. Of the 125 nonsyndromic cases, 25 cases had ultrasound soft marker findings ( Table 2) , 5 of which (20%) had pathogenic CNVs. This rate is similar to the pathogenic CNV rate for syndromic clefts (21.4%) and is also significantly higher (P = 0.02, Fisher's exact test) than the rate of pathogenic CNVs among the nonsyndromic cases without a soft marker (4/100, 4.0%). Among the syndromic cleft cases, CNS abnormalities (44.4%), muscle and skeletal defects (34.7%), and cardiac defects (32.6%) were the most frequently associated structural anomalies (Supplementary Table S3 online), similar to the results other studies. 13 The prevalence of pathogenic CNVs ranged from 11% to 42%, with none of the ultrasound findings having a statistically significantly higher prevalence than the other concurrent abnormalities. Two cases with incidental findings were excluded from the total. *P = 0.001, Fisher's exact test. P value assigned to the rate of pathogenic CNVs in the syndromic cases compared to the nonsyndromic cases.
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We evaluated the performance of CMA for detection of genomic alterations in a large cohort of prenatally detected oral clefts. Overall, 14.8% (40/270) of the cases had a pathogenic CNV ( Table 1) . Our multicenter cohort demonstrated that CMA was useful for uncovering submicroscopic pathogenic CNVs, which were undetectable by traditional chromosomal analysis. CMA increased the detection rate of chromosomal imbalances by 4.8% in the 190 cases with both CMA and chromosome analysis results (Supplementary Table S2 online). The capability of CMA to provide a more precise diagnosis included detection of a single-gene disorder: a 0.16-Mb Xq26.2 deletion in a male fetus (case 19) involving only one exon of the GPC3 gene and resulting in a diagnosis of Simpson-Golabi-Behmel syndrome (OMIM 312870). The precise diagnosis of prenatal cases has a profound impact on counseling and management and allows for better support for the family. Another striking example of the diagnostic capability of CMA is case 5, who presented with an isolated CLP by ultrasound and a small (1.6 Mb) deletion on 3q, revealing a diagnosis of 3q29 deletion syndrome. Without access to the information provided by CMA, counseling would have included the possibility of a favorable outcome following the repair of the CLP. Rather, by having the knowledge that the fetus actually had a 3q29 deletion, more accurate counseling including the associated variable dysmorphic features, intellectual disability, and autism spectrum presentation 14 was provided and allowed the parents to make more informed choices.
Further analysis of the cleft subgroups revealed several interesting observations about the prevalence of pathogenic CNVs. Unlike previous reports showing the lowest prevalence of chromosomal defects among the cleft lip-only cases, 7 our data from the cases with both CMA and chromosome analysis performed (Supplementary Table S2 online) showed that pathogenic CNVs in the CL subgroups were unexpectedly higher than those of the CLP cases in both groups. This finding indicates that the enhanced detection provided by CMA is especially impactful for CL cases. Alternatively, some of the CLP cases may be mistaken for CL due to the limitations of prenatal ultrasound. Another interesting finding was that 20% of the nonsyndromic cases with soft markers were detected with pathogenic CNVs; this rate is comparable to that of syndromic cases (21.4%). Interestingly, all three nonsyndromic cases with a single umbilical artery had pathogenic CNVs. This implies that soft markers may be indicative of those cases more likely to have a chromosomal abnormality. However, more samples should be recruited to confirm and evaluate which soft markers would have this diagnostic impact. Considering the major anomalies identified concurrently with the oral clefts, the prevalence of pathogenic CNVs was highest in cases with cardiac defects (23.4%), but it was not statistically significantly higher than the other two most common concurrent abnormalities (Supplementary Table S3 online) . Taken together, the data indicate that CMA is most likely to yield clinically useful information for syndromic cleft cases, regardless of specific concurrent anomalies, and for nonsyndromic cases with soft markers.
The higher-resolution analysis offered by CMA permits the opportunity to discover candidate genes related to oral clefting, further deepening our understanding of the development of the oral cavity. A genome-wide view of the CNVs detected in our study (trisomy 13 excluded) is presented in Supplementary  Figure S1 online, which highlights candidate loci for further evaluation. We dissected the recurrent or rare pathogenic CNVs detected in our cohort and analyzed the relationship of disrupted candidate genes with oral clefting. A recurrent 17p13.3 duplication was detected in two syndromic CLP cases. Hypotheses about the etiology of oral clefting in 17p13.3 duplications include duplication of YWHAE 15 and haploinsufficiency of ABR at the duplication breakpoint in the ABR region. 16 Both 17p13.3 duplications in our cohort contained YWHAE, but only one interrupted ABR. Hence, we are inclined to think that overdosage of YWHAE is related to oral clefting with variable penetrance. An atypical 1.2-Mb 22q11.2 deletion syndrome was detected in case 12 with syndromic CL, anal atresia, increased NT, and anotia. Unlike the 3-Mb common or 1.5-Mb nested DiGeorge syndrome deletions, TBX1 was not deleted in this case. However, this deletion disrupted CRKL, and in Crkl null mice, unfused shelves cause clefting, indicating its role in palatogenesis. 17, 18 We also found a rare duplication on 19p13.12 in case 31 that overlapped with the CNV of Decipher patient 249428 who presented with a high palate. Genes Syde1, Brd4, and Akap8 in this duplication are expressed in the branchial arches and frontonasal process at GD 10.5 of mouse embryos, which indicates their crucial role for palatogenesis. 19 Although CMA assists in the identification of candidate genes, functional studies to validate the role of these genes in oral clefting are required.
In addition to the advantages of CMA, genomic information that was not intended or relevant was also uncovered. Two cases with incidental findings (cases 41 and 42) had deletions that are probably unrelated to the oral cleft but still clinically significant: a carrier for Cohen syndrome (OMIM 216550) associated with hypotonia, microcephaly, intellectual disability, and joint hypermobility due to multiple exon deletions in VPS13B, and a late-onset disorder called hereditary neuropathy with liability to pressure palsies (OMIM 162500) that is due to 17p12 deletion involving PMP22 gene. Taking scenarios like this into consideration, both pretest and posttest counseling should be emphasized when applying CMA prenatally.
In conclusion, the risk of pathogenic CNVs in prenatally detected oral clefts ranged from as low as 6.7% in the a P = 0.0157, Fisher's exact test. P value assigned to pathogenic CNV rate in the cases with soft markers compared to those without soft markers.
nonsyndromic CL subgroup to as high as 26.1% in the syndromic CL subgroup. The improvement in the detection rate of CMA over chromosome analysis seen in our study strongly supports the value of CMA as a first-tier prenatal invasive test for syndromic oral clefts and nonsyndromic oral clefts with soft markers. Finally, by scrutinizing the gene content of the recurrent and rare CNVs in our cohort, we found that genes such as CRKL, AKAP8, SYDE1, and BRD4, shown to have critical functions in palatogenesis in animal models but not previously prioritized in humans, may be new candidate oral clefting genes.
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